The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB- CCOP) aims to provide increased access to state-of-the-art cancer prevention.care, and control .through NCI-sponsored clinical trials to the minority and indigent populations in the northwestern section of La., and throughout the state of Louisiana. The Feist-Weiller Cancer Center was established at the Louisiana State University Health Science Center in Shreveport (LSUHSC-S) to provide multidisciplinary cancer care, and clinical and translational research targeted to the unique population in Northwest La, which will improve the public health by decreasing cancer incidence and deaths. The population was plagued with high rates of poverty, low literacy and low levels of education, little access to modern approaches to prevention, detection, and treatment of cancer, and often presented with late stages of cancer. 55% of newly diagnosed cancer patients at LSUHSC-S are African-Americans. With the destruction of Charity and University Hospitals in New Orleans by hurricane Katrina, LSUHSC-S is now the only intact tertiary care hospital providing care to the .state's indigent and has become the major site for treatment of patients with leukemia, lymphomas and requiring bone marrow transplant. To provide local access to cancer clinical trials for the increased referal area.the FWCC plans to establish an organizational and operational base which will provide the structure to effectively implement a program to provide a multidisciplinary approach to cancer care and prevention for patients referred to the FWCC and in the patients' local comunities. The FWCC MB-CCOP will provide access to NCI-sponsored clinical trials, and research coordinator support. Education will be provided to community physicians through teleconferencing cancer tumor boards. Outreach programs to educate the indigent and minority population about cancer prevention, screening, and treatment, and clinical trials available through the FWCC MB-CCOP will be conducted w/ the assistance of the Louisiana Cancer Control Partnership, an organization dedicated to reducing cancer disparities by providng education, screening, referrals, information dissemination, and other resources in the minority and underserved communities. The FWCC has a history of >40% minority accrual to SWOG, CTSU, NCI, and industry treatment and prevention studies. Plans to expand minority acccess and accrual are detailed in this application. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA128567-02
Application #
7484241
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
2007-08-14
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
2
Fiscal Year
2008
Total Cost
$517,815
Indirect Cost
Name
Louisiana State University Hsc Shreveport
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
095439774
City
Shreveport
State
LA
Country
United States
Zip Code
71103
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 26 publications